Key result
In a series of 25 patients with infective endocarditis, rapid deployment aortic valve replacement was associated with a 4% 30-day mortality and no recurrent endocarditis at 11.1 months.
Why the study?
Does rapid deployment aortic valve replacement (RD-AVR) provide safe and effective outcomes in patients with infective endocarditis?
Does rapid deployment aortic valve replacement (RD-AVR) provide safe and effective outcomes in patients with infective endocarditis?
Answers are grounded in this paper and cite their sources.
Rapid deployment aortic valve replacement appears feasible in patients with infective endocarditis, but larger clinical trials with long-term follow-up are needed to confirm safety and efficacy.
Despite medical and surgical advances, the treatment of infective endocarditis (IE) remains challenging and is associated with considerable operative mortality and morbidity [1]. The two primary objectives of surgery are control of infection, by removing all infected and necrotic tissues, and reconstruction of cardiac morphology. In aortic valve endocarditis, while prosthetic valve replacement is the technique of choice, there is no clear consensus regarding which type of prosthesis yields superior outcomes. Thus, a tailored approach for each individual patient and the clinical situation is recommended [1]. Over the last decade, rapid deployment aortic valve replacement (RD-AVR) emerged as a valuable alternative to conventional AVR and was associated with excellent clinical results [2]. By simplifying the valve implantation process, RD-AVR was demonstrated to promote minimally invasive approaches, improve valve haemodynamics and facilitate valve implantation in challenging anatomical settings [2–5]. The study by Belyaev et al. [6] reports on surgical outcomes of 25 patients suffering from native or prosthetic valve endocarditis treated with RD valve prosthesis. Eleven patients (44%) received concomitant aortic root patch plasty due to root abscess. RD valve was implanted successfully in all patients, and no postoperative valve dislodgement occurred. Overall 30-day mortality was 4% and 2 patients (8%) received permanent pacemaker implantation. Echocardiographic data at 3 months showed a competent valve in all survived patients. No significant paravalvular leak or severe patient prosthesis mismatch was detected. At a mean follow-up of 11.1 months, no case of recurrent endocarditis occurred. To our knowledge, this is the largest series reporting on RD-AVR in IE and the authors have to be commended on the successful outcomes in these demanding and high-risk patients. Currently, the use of RD prostheses in the case of IE is still under investigation and the available evidence is limited to a few occasional reports [6, 7]. We agree with the authors that RD-AVR may carry some advantages over c-AVR in patients with IE. Indeed, the use of RD valve (i) reduces the need to pass sutures through friable tissues and minimize the use of foreign material (sutures and pledgets), (ii) improves valve sealing due to the expandable stent positioned into the LVOT and reduces sutures traction and mechanical solicitations to the frail and inflamed annulus that may lead to valve dehiscence, (iii) shortens cardiopulmonary bypass and cross-clamp times and (iv) improves valve haemodynamics. Nevertheless, while the results reported by the Munich group are promising, the published data are still underpowered and cannot support these assumptions (yet), apart from the feasibility of RD-AVR in IE [6, 7]. Thus, larger clinical trials with long-term observations are still needed to recommend the use of RD valves in patients with IE. Finally, the use of RD valve in patients presenting with root abscesses deserves a further comment. In the study by Belyaev et al. [6], 11 patients received RD-AVR and aortic root patch plasty with satisfactory early outcomes. It would be interesting if the authors reported on the anatomic extension of the root abscesses and the mid-/long-term results in such a subgroup of patients. Indeed, surgical repair of IE with extensive root involvement may be problematic and was associated with a significant incidence of the late patch and valve dehiscence [8]. Although small abscesses can be closed directly, extensive root abscesses should be kept draining into the pericardial cavity or circulation [1]. Accordingly, RD-AVR should be performed with caution in this anatomical setting [9] and root replacement with homograft or biological conduits must remain the treatment of choice [1, 10].
No takes yet. Share an insight, caveat, or question.
Berretta et al. (2022) conducted an editorial in Infective endocarditis (n=25). Rapid deployment aortic valve replacement (RD-AVR) was evaluated on 30-day mortality. In a series of 25 patients with infective endocarditis, rapid deployment aortic valve replacement was associated with a 4% 30-day mortality and no recurrent endocarditis at 11.1 months.
Synapse has enriched 10 related papers. Consider them for comparative context: